What is the global market size of Atopic Dermatitis Drugs Market?

Atopic Dermatitis Drugs Market size was valued at USD 12.5 billion in 2021 and is poised to grow from USD 13.65 billion in 2022 to USD 27.60 billion by 2030, growing at a CAGR of 9.2% during the forecast period (2023-2030).

Who are the key vendors in the Global Atopic Dermatitis Drugs Market?

The competitive landscape of the Global Atopic Dermatitis Drugs Market is characterized by intense competition among key players in the pharmaceutical industry. These companies are engaged in extensive research and development activities to develop innovative drugs and therapies for the effective management of atopic dermatitis. There is a focus on developing targeted and personalized treatment options to cater to the specific needs of patients. Additionally, strategic collaborations, partnerships, and licensing agreements are prevalent in the market as companies seek to expand their product portfolios and enhance their market presence. Market players are also investing in marketing and promotional activities to increase awareness about their products and gain a competitive edge. 'Pfizer Inc. (US)', 'Sanofi (France)', 'AbbVie Inc. (US)', 'GALDERMA LABORATORIES, L.P. (Switzerland)', 'Eli Lilly and Company (US)', 'Regeneron Pharmaceuticals Inc. (US)', 'LEO Pharma Inc. (Denmark)', 'Otsuka Pharmaceutical Co., Ltd. (Japan)', 'Novartis AG (Switzerland)', 'Incyte Corporation (US)', 'Astellas Pharma Inc. (Japan)', 'Bristol Myers Squibb (US)', 'Johnson & Johnson (US)', 'Takeda Pharmaceutical Company Limited (Japan)', 'GlaxoSmithKline plc (UK)', 'Boehringer Ingelheim International GmbH (Germany)', 'Celgene Corporation (US)', 'Meda AB (Sweden)', 'Pierre Fabre Group (France)', 'Bayer AG (Germany)'

What is the key driver of Global Atopic Dermatitis Drugs Market?

One key driver for the Global Atopic Dermatitis Drugs Market is the increasing prevalence of atopic dermatitis worldwide. Atopic dermatitis is a common and chronic inflammatory skin condition that affects a significant number of individuals globally, including both children and adults. The rising incidence of atopic dermatitis can be attributed to various factors such as genetic predisposition, environmental triggers, and lifestyle changes. The growing prevalence of atopic dermatitis is driving the demand for effective treatment options to alleviate the symptoms and improve the quality of life for affected individuals. This increased demand has created a favorable market environment for pharmaceutical companies to develop and introduce new drugs and therapies.

What is the key market trend for Global Atopic Dermatitis Drugs Market?

One key market trend in the Global Atopic Dermatitis Drugs Market is the increasing focus on biologic therapies. Biologic agents, such as monoclonal antibodies, have gained significant attention and acceptance in the treatment of moderate to severe atopic dermatitis. These therapies target specific molecules and pathways involved in the immune response associated with the condition, providing a targeted approach to managing the disease. The trend towards biologic therapies is driven by their high efficacy and potential for long-lasting remission, offering a promising treatment option for patients who have not responded well to traditional therapies. This trend reflects a shift towards precision medicine and personalized treatment approaches in the field of atopic dermatitis.

Which region accounted for the largest share in Atopic Dermatitis Drugs Market?

North America dominated the Global Atopic Dermatitis Drugs Market. This can be attributed to several factors, including the high prevalence of atopic dermatitis in the region, advanced healthcare infrastructure, robust research and development activities, and favorable reimbursement policies. North America is home to major pharmaceutical companies and research institutions focused on developing innovative therapies for atopic dermatitis, driving market dominance in the region.

Atopic Dermatitis Drugs Market Size, Share, Growth Analysis, By Drug Class(Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics), By Route Of Administration(Topical, Injectable, Oral), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region - Industry Forecast 2025-2032

Report ID: SQMIG35I2166 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 62 | Figures: 75

Atopic Dermatitis Drugs Market News

In September 2024, Eli Lilly and Company, a leading pharmaceutical organization announced that the United States Food and Drug Administration (FDA) approved its new treatment for atopic dermatitis. EBGLYSS™ (lebrikizumab-lbkz) was approved for use in adults and children aged 12 and above.
In July 2024, the FDA approved a supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream. The new treatment for mild to moderate atopic dermatitis is developed by Arcutis Biotherapeutics Inc. And suitable for use in patients aged 6 and above.
In January 2024, in a collaborative effort Glenmark Pharmaceuticals and Pfizer launched an oral treatment for moderate to servere atopic dermatitis for the Indian market. Abrocitinib is being sold in India under the brand name JABRYUS and CIBINQO to improve accessibility to dermatitis treatment in the country.

Atopic Dermatitis Drugs Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Atopic Dermatitis Drugs Market size was valued at USD 13.65 billion in 2022 and is poised to grow from USD 14.91 billion in 2023 to USD 30.14 billion by 2031, growing at a CAGR of 9.2% during the forecast period (2024-2031).

Atopic dermatitis drug suppliers should focus on expanding their business scope across multiple regions to boost sales in the future. Developing affordable yet effective biologic drugs is slated to be the prime focus of almost all atopic dermatitis drug companies going forward. Acquiring product approvals from regulatory bodies and increasing awareness regarding atopic dermatitis are also key strategies for atopic dermatitis drug providers in the long run. 'Pfizer Inc. (US)', 'Sanofi (France)', 'AbbVie Inc. (US)', 'GALDERMA LABORATORIES, L.P. (Switzerland)', 'Eli Lilly and Company (US)', 'Regeneron Pharmaceuticals Inc. (US)', 'LEO Pharma Inc. (Denmark)', 'Otsuka Pharmaceutical Co., Ltd. (Japan)', 'Novartis AG (Switzerland)', 'Incyte Corporation (US)', 'Astellas Pharma Inc. (Japan)', 'Bristol Myers Squibb (US)', 'Johnson & Johnson (US)', 'Takeda Pharmaceutical Company Limited (Japan)', 'GlaxoSmithKline plc (UK)', 'Boehringer Ingelheim International GmbH (Germany)', 'Celgene Corporation (US)', 'Meda AB (Sweden)', 'Pierre Fabre Group (France)', 'Bayer AG (Germany)'

Rising prevalence of atopic dermatitis around the world owing to changes in environment, urbanization, and genetic predisposition are expected to boost the demand for atopic dermatitis drugs over the coming years. The incidence of atopic dermatitis is slated to be especially high among children and young adults going forward.

Use of JAK Inhibitors: Atopic dermatitis drug providers should focus on the use of JAK (Janus kinase) inhibitors to maximize their business scope in the future. rapid symptom relief and addressing unmet needs of patients affected from atopic dermatitis are benefits of using JAK inhibitors such as upadacitinib and abrocitinib. Focusing on the use of JAK inhibitors is slated to emerge as a prominent atopic dermatitis drugs market trend through 2031.

The presence of leading atopic dermatitis drug providers allows North America to account for a prominent chunk of the global atopic dermatitis drugs market size in the future. High healthcare spending potential, high prevalence of dermatological diseases, and availability of favorable reimbursement policies are estimated to further cement the dominance of North American region. The United States is estimated to bring in the most revenue for atopic dermatitis drug providers looking to make a mark in this region. Rising investments in R&D of novel dermatitis treatments and frequent product approvals are also creating new opportunities for atopic dermatitis drug suppliers in North America.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Atopic Dermatitis Drugs Market News

Atopic Dermatitis Drugs Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Atopic Dermatitis Drugs Market?

Who are the key vendors in the Atopic Dermatitis Drugs Market?

What is the key driver of Atopic Dermatitis Drugs Market?

What is the key market trend for Atopic Dermatitis Drugs Market?

Which region accounted for the largest share in Atopic Dermatitis Drugs Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300